Skye Bioscience (SKYE) Common Equity (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Common Equity of $9.0 million for Q1 2026, down 84.79% year-over-year from $59.3 million in Q1 2025, and down 55.0% quarter-over-quarter from $20.0 million in Q4 2025.
Skye Bioscience (SKYE) Common Equity (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Common Equity for 15 consecutive years, with $9.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 84.79% year-over-year to $9.0 million; the TTM figure through Mar 2026 stood at $9.0 million (down 84.79% YoY), while the FY2025 annual figure was $20.0 million, down 70.62% from the prior year.
- Common Equity fell to $9.0 million in Q1 2026 per SKYE's latest filing, from $20.0 million in the prior quarter.
- Across five years, Common Equity topped out at $78.9 million in Q1 2024 and bottomed at -$7.8 million in Q2 2023.
- Historically, Common Equity has averaged $26.1 million across 5 years, with a median of $9.0 million in 2026.
- Annual changes were most pronounced in 2023 — Common Equity tumbled 2480.73% — and 2024, when it jumped 4371.49%.
- Skye Bioscience's Common Equity stood at -$3.0 million in 2022, then rose by 29.13% to -$2.1 million in 2023, then jumped by 3296.88% to $68.2 million in 2024, then sank by 70.62% to $20.0 million in 2025, then plunged by 55.0% to $9.0 million in 2026.
- Business Quant data shows SKYE's Common Equity at $9.0 million in Q1 2026, $20.0 million in Q4 2025, and $32.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | 9.79 Bn |
| 10 | Skye Bioscience | 10.68 Mn | 10.68 Mn | - | -497,307.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.01 Mn |
| Dec 31, 2025 | 20.02 Mn |
| Sep 30, 2025 | 32.84 Mn |
| Jun 30, 2025 | 43.68 Mn |
| Mar 31, 2025 | 59.25 Mn |
| Dec 31, 2024 | 68.15 Mn |
| Sep 30, 2024 | 75.80 Mn |
| Jun 30, 2024 | 72.81 Mn |
| Mar 31, 2024 | 78.88 Mn |
| Dec 31, 2023 | -2.13 Mn |
| Sep 30, 2023 | 1.70 Mn |
| Jun 30, 2023 | -7.79 Mn |
| Mar 31, 2023 | -4.78 Mn |
| Dec 31, 2022 | -3.01 Mn |
| Sep 30, 2022 | -3.28 Mn |
| Jun 30, 2022 | -301,822.00 |
| Mar 31, 2022 | 2.97 Mn |
| Dec 31, 2021 | 5.86 Mn |
| Sep 30, 2021 | 8.26 Mn |
| Jun 30, 2021 | 2.27 Mn |